NIKKEI 225
38,298.06 +95.69 (+0.25%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
79.28 +0.29 (+0.37%) GOLD FUTURES
2,316.30 -6.00 (-0.26%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,134.95 -1,000.65 (-2.00%)
Caribou Biosciences, Inc. (CRBU)
After hours:
| Previous close | 3.7300 |
| Open | 3.6400 |
| Bid | 3.4900 x 400 |
| Ask | 3.5200 x 800 |
| Day's range | 3.4400 - 3.7000 |
| 52-week range | 3.4400 - 8.5900 |
| Volume | |
| Avg. volume | 1,623,375 |
| Market cap | 316.112M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple milestones ahead -- -- $345.9 million in cash, cash
- GlobeNewswire
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: 2024 RBC Capital Markets Global Healthcare Conference, New York, NYMay 14, 2024, fireside chat at 3:35 pm EDTWebcast BofA Securities 2024 Health Care Conference, Las Vegas, NVMay 15, 2024, corporate presentation at 3:40 pm PDTWebcast For more informa
- GlobeNewswire
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois. The ANTLER poster will provide initial dose expansion data. Details of the poster presentation are as follows: Title: A CRI
